- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Transplantation
Volume 2012 (2012), Article ID 230870, 9 pages
Islet -Cell Mass Preservation and Regeneration in Diabetes Mellitus: Four Factors with Potential Therapeutic Interest
Pancreatic Islet Development and Regeneration Unit, Department of Stem Cells, CABIMER-Andalusian Center for Molecular Biology and Regenerative Medicine, Avenida Américo Vespucio, Parque Científico y Tecnológico Cartuja 93, 41092 Sevilla, Spain
Received 25 May 2012; Revised 5 July 2012; Accepted 6 July 2012
Academic Editor: Thierry Berney
Copyright © 2012 Jose Manuel Mellado-Gil et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. D. Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 35, supplement 1, pp. S64–S71, 2012.
- B. Keymeulen, M. Walter, C. Mathieu et al., “Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass,” Diabetologia, vol. 53, no. 4, pp. 614–623, 2010.
- D. M. Harlan, N. S. Kenyon, O. Korsgren, and B. O. Roep, “Current advances and travails in islet transplantation,” Diabetes, vol. 58, no. 10, pp. 2175–2184, 2009.
- E. A. Ryan, B. W. Paty, P. A. Senior et al., “Five-year follow-up after clinical islet transplantation,” Diabetes, vol. 54, no. 7, pp. 2060–2069, 2005.
- H. Johansson, A. Lukinius, L. Moberg et al., “Tissue factor produced by the endocrine cells of the islets of langerhans is associated with a negative outcome of clinical islet transplantation,” Diabetes, vol. 54, no. 6, pp. 1755–1762, 2005.
- Y. Saito, M. Goto, K. Maya et al., “Brain death in combination with warm ischemic stress during isolation procedures induces the expression of crucial inflammatory mediators in the isolated islets,” Cell Transplantation, vol. 19, no. 6-7, pp. 775–782, 2010.
- A. M. J. Shapiro, J. R. T. Lakey, E. A. Ryan et al., “Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen,” New England Journal of Medicine, vol. 343, no. 4, pp. 230–238, 2000.
- J. Tjernberg, K. N. Ekdahl, J. D. Lambris, O. Korsgren, and B. Nilsson, “Acute antibody-mediated complement activation mediates lysis of pancreatic islets cells and may cause tissue loss in clinical islet transplantation,” Transplantation, vol. 85, no. 8, pp. 1193–1199, 2008.
- O. Naujok, C. Burns, P. M. Jones, and S. Lenzen, “Insulin-producing surrogate β-cells from embryonic stem cells: are we there yet?” Molecular Therapy, vol. 19, pp. 1759–1768, 2011.
- M. M. Sachdeva and D. A. Stoffers, “Minireview: meeting the demand for insulin: molecular mechanisms of adaptive postnatal β-cell mass expansion,” Molecular Endocrinology, vol. 23, no. 6, pp. 747–758, 2009.
- S. Sreenan, A. J. Pick, M. Levisetti, A. C. Baldwin, W. Pugh, and K. S. Polonsky, “Increased β-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse,” Diabetes, vol. 48, no. 5, pp. 989–996, 1999.
- N. A. Sherry, J. A. Kushner, M. Glandt, T. Kitamura, A. M. B. Brillantes, and K. C. Herold, “Effects of autoimmunity and immune therapy on β-cell turnover in type 1 diabetes,” Diabetes, vol. 55, no. 12, pp. 3238–3245, 2006.
- L. Trusolino, A. Bertotti, and P. M. Comoglio, “MET signalling: principles and functions in development, organ regeneration and cancer,” Nature Reviews Molecular Cell Biology, vol. 11, no. 12, pp. 834–848, 2010.
- S. P. S. Monga, W. M. Mars, P. Pediaditakis et al., “Hepatocyte growth factor induces Wnt-independent nuclear translocation of β-catenin after Met-β-catenin dissociation in hepatocytes,” Cancer Research, vol. 62, no. 7, pp. 2064–2071, 2002.
- C. G. Huh, V. M. Factor, A. Sánchez, K. Uchida, E. A. Conner, and S. S. Thorgeirsson, “Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 13, pp. 4477–4482, 2004.
- T. Nakamura, K. Sakai, T. Nakamura, and K. Matsumoto, “Hepatocyte growth factor twenty years on: much more than a growth factor,” Journal of Gastroenterology and Hepatology, vol. 26, supplement 1, pp. 188–202, 2011.
- C. Demirci, S. Ernst, J. C. Alvarez-Perez, et al., “Loss of HGF/c-met signaling in pancreatic beta-cells leads to incomplete maternal beta-cell adaptation and gestational diabetes mellitus,” Diabetes, vol. 61, pp. 1143–1152, 2012.
- J. Mellado-Gil, T. C. Rosa, C. Demirci et al., “Disruption of hepatocyte growth factor/c-Met signaling enhances pancreatic β-cell death and accelerates the onset of diabetes,” Diabetes, vol. 60, no. 2, pp. 525–536, 2011.
- A. García-Ocaña, K. K. Takane, V. T. Reddy, J. C. Lopez-Talavera, R. C. Vasavada, and A. F. Stewart, “Adenovirus-mediated hepatocyte growth factor expression in mouse islets improves pancreatic islet transplant performance and reduces beta cell death,” Journal of Biological Chemistry, vol. 278, no. 1, pp. 343–351, 2003.
- J. C. Lopez-Talavera, A. Garcia-Ocaña, I. Sipula, K. K. Takane, I. Cozar-Castellano, and A. F. Stewart, “Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation,” Endocrinology, vol. 145, no. 2, pp. 467–474, 2004.
- N. M. Fiaschi-Taesch, D. M. Berman, B. M. Sicari et al., “Hepatocyte growth factor enhances engraftment and function of nonhuman primate islets,” Diabetes, vol. 57, no. 10, pp. 2745–2754, 2008.
- X. Y. Li, X. R. Zhan, C. Lu, X. M. Liu, and X. C. Wang, “Mechanisms of hepatocyte growth factor-mediated signaling in differentiation of pancreatic ductal epithelial cells into insulin-producing cells,” Biochemical and Biophysical Research Communications, vol. 398, no. 3, pp. 389–394, 2010.
- X. R. Zhan, X. Y. Li, X. M. Liu et al., “Generation of insulin-secreting cells from adult rat pancreatic ductal epithelial cells induced by hepatocyte growth factor and betacellulin-δ4,” Biochemical and Biophysical Research Communications, vol. 382, no. 2, pp. 375–380, 2009.
- L. L. Baggio and D. J. Drucker, “Biology of incretins: GLP-1 and GIP,” Gastroenterology, vol. 132, no. 6, pp. 2131–2157, 2007.
- N. Herbach, B. Goeke, M. Schneider, W. Hermanns, E. Wolf, and R. Wanke, “Overexpression of a dominant negative GIP receptor in transgenic mice results in disturbed postnatal pancreatic islet and beta-cell development,” Regulatory Peptides, vol. 125, no. 1–3, pp. 103–117, 2005.
- N. Herbach, M. Bergmayr, B. Göke, E. Wolf, and R. Wanke, “Postnatal development of numbers and mean sizes of pancreatic islets and beta-cells in healthy mice and giprdn transgenic diabetic mice,” PLoS ONE, vol. 6, no. 7, Article ID e22814, 2011.
- S. J. Kim, K. Winter, C. Nian, M. Tsuneoka, Y. Koda, and C. H. S. McIntosh, “Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic β-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the Forkhead transcription factor Foxo1, and down-regulation of bax expression,” Journal of Biological Chemistry, vol. 280, no. 23, pp. 22297–22307, 2005.
- S. J. Kim, C. Nian, S. Widenmaier, and C. H. S. McIntosh, “Glucose-dependent insulinotropic polypeptide-mediated up-regulation of β-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2,” Molecular and Cellular Biology, vol. 28, no. 5, pp. 1644–1656, 2008.
- V. Lyssenko, L. Eliasson, O. Kotova, et al., “Pleiotropic effects of GIP on islet function involve osteopontin,” Diabetes, vol. 60, pp. 2424–2433, 2012.
- S. B. Widenmaier, S. J. Kim, G. K. Yang et al., “A GIP receptor agonist exhibits β-cell anti-apoptotic actions in rat models of diabetes resulting in improved β-cell function and glycemic control,” PLoS ONE, vol. 5, no. 3, Article ID e9590, 2010.
- B. N. Friedrichsen, N. Neubauer, Y. C. Lee et al., “Stimulation of pancreatic β-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways,” Journal of Endocrinology, vol. 188, no. 3, pp. 481–492, 2006.
- B. Sosa-Pineda, K. Chowdhury, M. Torres, G. Oliver, and P. Gruss, “The Pax4 gene is essential for differentiation of insulin-producing β cells in the mammalian pancreas,” Nature, vol. 386, no. 6623, pp. 399–402, 1997.
- A. L. Greenwood, S. Li, K. Jones, and D. A. Melton, “Notch signaling reveals developmental plasticity of Pax4+ pancreatic endocrine progenitors and shunts them to a duct fate,” Mechanisms of Development, vol. 124, no. 2, pp. 97–107, 2007.
- T. Brun, I. Franklin, L. St.-Onge L. et al., “The diabetes-linked transcription factor Pax4 promotes β-cell proliferation and survival in rat and human islets,” Journal of Cell Biology, vol. 167, no. 6, pp. 1123–1135, 2004.
- T. Brun, K. H. H. He, R. Lupi et al., “The diabetes-linked transcription factor Pax4 is expressed in human pancreatic islets and is activated by mitogens and GLP-1,” Human Molecular Genetics, vol. 17, no. 4, pp. 478–489, 2008.
- Y. Li, H. Nagai, T. Ohno et al., “Aberrant DNA demethylation in promoter region and aberrant expression of mRNA of Pax4 gene in hematologic malignancies,” Leukemia Research, vol. 30, no. 12, pp. 1547–1553, 2006.
- T. Miyamoto, T. Kakizawa, K. Ichikawa, S. Nishio, S. Kajikawa, and K. Hashizume, “Expression of dominant negative form of Pax4 in human insulinoma,” Biochemical and Biophysical Research Communications, vol. 282, no. 1, pp. 34–40, 2001.
- T. Brun and B. R. Gauthier, “A focus on the role of Pax4 in mature pancreatic islet β-cell expansion and survival in health and disease,” Journal of Molecular Endocrinology, vol. 40, no. 1-2, pp. 37–45, 2008.
- J. Lu, G. Li, M. S. Lan et al., “Pax4 paired domain mediates direct protein transduction into mammalian cells,” Endocrinology, vol. 148, no. 11, pp. 5558–5565, 2007.
- T. Brun, D. L. Duhamel, K. H. Hu He, C. B. Wollheim, and B. R. Gauthier, “The transcription factor Pax4 acts as a survival gene in INS-1E insulinoma cells,” Oncogene, vol. 26, no. 29, pp. 4261–4271, 2007.
- K. H. H. He, P. I. Lorenzo, T. Brun et al., “In vivo conditional Pax4 overexpression in mature islet β-cells prevents stress-induced hyperglycemia in mice,” Diabetes, vol. 60, no. 6, pp. 1705–1715, 2011.
- P. Collombat, X. Xu, P. Ravassard et al., “The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into α and subsequently β cells,” Cell, vol. 138, no. 3, pp. 449–462, 2009.
- F. Thorel, V. Népote, I. Avril et al., “Conversion of adult pancreatic α-cells to β-cells after extreme β-cell loss,” Nature, vol. 464, no. 7292, pp. 1149–1154, 2010.
- C. H. Chung, E. Hao, R. Piran, E. Keinan, and F. Levine, “Pancreatic β-cell neogenesis by direct conversion from mature α-cells,” Stem Cells, vol. 28, no. 9, pp. 1630–1638, 2010.
- J. Lu, P. L. Herrera, C. Carreira et al., “α cell-specific men1 ablation triggers the transdifferentiation of glucagon-expressing cells and insulinoma development,” Gastroenterology, vol. 138, no. 5, pp. 1954–1965, 2010.
- L. Galarneau, J. F. Paré, D. Allard et al., “The α1-fetoprotein locus is activated by a nuclear receptor of the Drosophila FTZ-F1 family,” Molecular and Cellular Biology, vol. 16, no. 7, pp. 3853–3865, 1996.
- E. Fayard, K. Schoonjans, J. S. Annicotte, and J. Auwerx, “Liver receptor homolog 1 controls the expression of carboxyl ester lipase,” Journal of Biological Chemistry, vol. 278, no. 37, pp. 35725–35731, 2003.
- F. M. Rausa, L. Galarneau, L. Bélanger, and R. H. Costa, “The nuclear receptor fetoprotein transcription factor is coexpressed with its target gene HNF-3β in the developing murine liver intestine and pancreas,” Mechanisms of Development, vol. 89, no. 1-2, pp. 185–188, 1999.
- O. A. Botrugno, E. Fayard, J. S. Annicotte et al., “Synergy between LRH-1 and β-catenin Induces G1 cyclin-mediated cell proliferation,” Molecular Cell, vol. 15, no. 4, pp. 499–509, 2004.
- D. Boerboom, N. Pilon, R. Behdjani, D. W. Silversides, and J. Sirois, “Expression and regulation of transcripts encoding two members of the NR5A nuclear receptor subfamily of orphan nuclear receptors, steroidogenic factor-1 and NR5A2, in equine ovarian cells during the ovulatory process,” Endocrinology, vol. 141, no. 12, pp. 4647–4656, 2000.
- Y. K. Lee and D. D. Moore, “Liver receptor homolog-1, an emerging metabolic modulator,” Frontiers in Bioscience, vol. 13, pp. 5950–5958, 2008.
- N. Venteclef, J. C. Smith, B. Goodwin, and P. Delerive, “Liver receptor homolog 1 is a negative regulator of the hepatic acute-phase response,” Molecular and Cellular Biology, vol. 26, no. 18, pp. 6799–6807, 2006.
- C. Benod, M. V. Vinogradova, N. Jouravel, G. E. Kim, R. J. Fletterick, and E. P. Sablin, “Nuclear receptor liver receptor homologue 1 (LRH-1) regulates pancreatic cancer cell growth and proliferation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, pp. 16927–16931, 2011.
- M. Baquié, L. St-Onge, J. Kerr-Conte et al., “The liver receptor homolog-1 (LRH-1) is expressed in human islets and protects β-cells against stress-induced apoptosis,” Human Molecular Genetics, vol. 20, no. 14, Article ID ddr193, pp. 2823–2833, 2011.
- F. Delaunay, A. Khan, A. Cintra et al., “Pancreatic β cells are important targets for the diabetogenic effects of glucocorticoids,” Journal of Clinical Investigation, vol. 100, no. 8, pp. 2094–2098, 1997.
- C. Lambillotte, P. Gilon, and J. C. Henquin, “Direct glucocorticoid inhibition of insulin secretion: an in vitro study of dexamethasone effects in mouse islets,” Journal of Clinical Investigation, vol. 99, no. 3, pp. 414–423, 1997.
- T. Lund, B. Fosby, O. Korsgren, H. Scholz, and A. Foss, “Glucocorticoids reduce pro-inflammatory cytokines and tissue factor in vitro and improve function of transplanted human islets in vivo,” Transplant International, vol. 21, no. 7, pp. 669–678, 2008.
- S. Turban, X. Liu, L. Ramage, et al., “Optimal elevation of beta-cell 11beta-hydroxysteroid dehydrogenase type 1 is a compensatory mechanism that prevents high-fat diet-induced beta-cell failure,” Diabetes, vol. 61, pp. 642–652, 2012.
- E. A. Ortlund, Y. Lee, I. H. Solomon et al., “Modulation of human nuclear receptor LRH-1 activity by phospholipids and SHP,” Nature Structural and Molecular Biology, vol. 12, no. 4, pp. 357–363, 2005.
- J. M. Lee, Y. K. Lee, J. L. Mamrosh et al., “A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects,” Nature, vol. 474, no. 7352, pp. 506–510, 2011.
- R. J. Whitby, J. Stec, R. D. Blind et al., “Small molecule agonists of the orphan nuclear receptors steroidogenic factor-1 (SF-1, NR5A1) and liver receptor homologue-1 (LRH-1, NR5A2),” Journal of Medicinal Chemistry, vol. 54, no. 7, pp. 2266–2281, 2011.
- S. Y. Perl, J. A. Kushner, B. A. Buchholz et al., “Significant human β-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 10, pp. E234–E239, 2010.
- N. Cobo-Vuilleumier and B. R. Gauthier, “To β-e or not to β-e replicating after 30: retrospective dating of human pancreatic islets,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 10, pp. 4552–4554, 2010.